Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 8.45p 8.10p 8.80p 8.45p 8.45p 8.45p 0 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.8 -0.5 -0.2 - 18

Eden Research Share Discussion Threads

Showing 6976 to 6998 of 8200 messages
Chat Pages: Latest  280  279  278  277  276  275  274  273  272  271  270  269  Older
DateSubjectAuthorDiscuss
09/5/2019
06:08
In the Market place..News Bioline Iberia opens a biofactory with capacity for 100 million organisms for biological control hTTp://agrodiariohuelva.es/2019/05/08/bioline-iberia-abre-una-biofabrica-con-capacidad-para-100-millones-de-organismos-para-control-biologico/ Bioline Iberia has inaugurated a new 'Biofactory' in the municipality of El Ejido (Almería), in the presence of the leaders of the French Union of Cooperatives InVivo, its vice-president Jérôme Calleau, and its general director Thierry Blandinières; and the leaders of the associated Spanish cooperatives, Cristóbal Barranco, president of SUCA and Manuel Galdeano, president of COEXPHAL; the territorial delegate of the Junta de Andalucía de Agricultura, Aránzazu Martín; and the mayor Francisco Góngora. The team. In January, Bioline Agrosciences and the company Biocolor (Spain) announced the creation of a new company, Bioline Iberia, which has just opened this production plant. The new 4,000 m2 building has been transformed into a biofactory in a record time of less than six months. Dozens of high technology rooms have been installed for the production of auxiliary insects, which are expected to reach a figure of 100 billion organisms beneficial for the biological control of pests. It also has modern packing equipment and the result of this project has already created 27 jobs. The choice of El Ejido in the heart of the greenhouses of Almería should be put into perspective with our growth ambitions and our strategic plan to permanently establish ourselves in one of the most important biocontrol markets in the world: the Iberian Peninsula with Spain and Portugal and Morocco », said Ludwik Pokorny, CEO of Bioline Agrosciences. "This is the union of two roads that began a while ago and we agree on the same goal: to make available to agricultural producers the necessary tools so that their productions earn in agro-food security, are respectful with the environment and sustainable in the time, "said José Antonio Rodríguez, president of Bioline Iberia. "The construction of this biofactory is designed to meet the needs of the client and to bring together the production and supply of beneficial insects for farmers and user cooperatives," said Mª José Pardo, executive director of Bioline Iberia. Spanish and French cooperatives «The investment of Bioline Agrosciences in the region is a good example of cooperation between Spanish and French cooperatives, with the aim of offering Andalusian farmers the best of current biocontrol technology and enabling them to overcome the challenges they face, such as They are offering consumers a more sustainable food, with a minimum of waste, "said Thierry Blandinières, CEO of InVivo. In this union, Biocolor has contributed a well positioned brand in the cooperative segment and a solid reputation for its exceptional quality of service. Bioline Agrosciences has an internationally renowned brand, an important portfolio of products and technical knowledge, as well as innovative biocontrol solutions. Since November 2018, Bioline Iberia has been distributing predatory mites for the greenhouse market in the province of Almeria, an area that supplies up to 60% of the fruit and vegetable market in northern Europe.
supersonico
08/5/2019
20:52
carey gillam@careygillam Plaintiff attorney in Pilliod v Monsanto tells jurors to consider $1 billion punitive damage award to send message to @Bayer “They need to pay” Dorothy M. Atkins@doratki He said that’s the amount that will make Monsanto executives notice and at least one exec even referred to glyphosate’s safety as “the billion-dollar question” in internal emails. The Pilliods’ total ask is about $1.55 billion. With that, plaintiffs wrapped their closings and we’re on an hr lunch break before Monsanto is up.
supersonico
08/5/2019
19:17
hTTps://thecontraryfarmer.wordpress.com/2013/02/13/pigweed-is-bringing-us-to-our-knees/ It's been happening for a few years according to this farmer Ft link is subscription I think
33mick
08/5/2019
18:34
There goes another one..news California Governor Gavin Newsom cancels registration of brain-damaging pesticide chlorpyrifos Sacramento, CA- Today, leaders with California Governor Gavin Newsom’s administration announced a historic decision to initiate the process to cancel the registration for use in the state of the neurodevelopmental toxicant pesticide chlorpyrifos. Robust studies have linked prenatal exposure to chlorpyrifos to children developing autism, ADHD and other neurodevelopmental conditions. The Governor’s office also announced that $5.7 million will be earmarked to identify and implement alternatives to chlorpyrifos, including research into biological pesticides, and a new focus on integrated pest management. hTTp://www.panna.org/press-statement/california-governor-gavin-newsom-cancels-registration-brain-damaging-pesticide?utm_source=web&utm_medium=tw&utm_campaign=kids
supersonico
08/5/2019
11:00
The share price is also 15p lower than an intraday high some 3 years ago. Given our progress since, this is quite ridiculous. Picking up on wans post re Sustaine, I expect Eden/advisers to soon start pricing some of that in to their projection forecasts looking forward, typically, 3 years. That should make the investment proposition, extremely and unavoidably, attractive.
investingisatrickygame
08/5/2019
08:43
The share price is currently approximately 1.8p lower than it was at the time of last year's AGM. The Chairman needs to do something about this in extremely short order, before this year's AGM (6 days time) to avoid embarrassment. Could someone attending this year's AGM ask the Chairman what he meant by the phrase "in short order"?
weyweyumfozo
08/5/2019
07:46
Investing, Cambrian moments take time;)
supersonico
08/5/2019
07:39
Maybe, but investors had not previously heard that; "Sustaine™, which is being tested by a number of third parties, including some of the major agchem companies" There is perhaps some urgency in terms of "the clock is ticking down rapidly"(which I am not feeling), but I don't believe that is from Eden's perspective. However, there may indeed be some urgency, given the increased interest, on those "third parties" to complete the testing of Sustaine and to thus enter/finalise negotiations. Further patience is needed, so just keep in mind that Sustaine does what it says on the tin and that validation is strengthening rapidly, but its potential is far from being realised!
wan
07/5/2019
22:10
FYI, Eden is not.
investingisatrickygame
07/5/2019
20:03
Aims, potentially, in short order... we've heard these words a few times???I am hopeful but the clock is ticking down rapidly...
bjlk
07/5/2019
16:12
Bjlk...Just to remind you what the Chairman stated in the AR; "Whilst the financial results for 2018 are again pleasing, there is a lot of upside potential which the Company aims to realise. There are a number of products, in addition to Mevalone and Cedroz which Eden is in the advanced stages of developing. The new products in the Company’s pipeline aim to address markets which are potentially bigger than those already covered by its existing products and are creating a healthy pipeline of growth opportunities for Eden." "There is potential for an even greater opportunity around the use of Eden’s proprietary, natural micro-encapsulation technology, Sustaine™, which is being tested by a number of third parties, including some of the major agchem companies."
wan
07/5/2019
15:54
I really hope all this is going on in the background as sometimes it's very hard to detect anything going on at all..
bjlk
07/5/2019
15:21
Brucie...If I am anywhere near right, Bayer might be very interested in partnering with the head lice product (but I am not saying it's them yet!) and possibly also be very interested in other products and in particular Eden's novel encapsualtion and delivery platform, Sustaine. What I am also suggesting, is that Bayer can effectively lock Eden's AH products out of the US (by stalling or even requiring further formulation work!)......however, that agreement was based on an earlier (but still effective) encapsulation technology, so it's possible that the exclusivity previously agreed with Bayer may 'not' prevent Eden agreeing to launch with another party using the latest generation of encapsulation technology. I believe the strength of Eden's intellectual property portfolio is already evident in terms of their existing partners involvement and investments, not to mention that those partners have their own 'extensive' patent portfolio's and expertise. Regulatory approvals will further cement that strength and further strengthen Eden's negotiating hand, not to mention strengthen the share price, hence we need to maintain our patience. To quote from my title post - "In order to fully and effectively exploit the inherent advantages of these new and less stable products, new formulation, stabilization and delivery technologies will be required. Thus, a very large opportunity is presenting itself, and if Eden's delivery technologies could address only a small percentage of this market, it would transform the company!" The Chairman has clearly recognised the potential in Sustain (and he should know), and with momentum building in terms of product authorisation and validation, along with new interest, a couple of AH products not being launched will neither break the bank, nor stop Sustaine ultimately becoming a success. So, it's also possible that Eden itself may be playing hard ball, but for all the right reasons and a strengthening hand!
wan
07/5/2019
15:04
fyi..SEE is stirring.
supersonico
07/5/2019
14:18
Wan, should have said Thanks for the links and digging around. Good job
brucie5
07/5/2019
14:18
Wan, should have said Thanks for the links and digging around. Good job
brucie5
07/5/2019
12:35
Ok, so to be crystal clear, you surmise that Bayer are the crypto-partner for TT as well as the stated partner for CAP; and that they are unhappy to be out of the loop for Sustaine, so using the CAP/TT delays as a way of advancing their negotiating hand with whatever is progressing behind closed doors at Sustaine, in which, we presume, they have a seat at the table. (Why would they not?) Sorry to be so plain. But I think that's what you're saying?
brucie5
07/5/2019
11:25
Brucie...Call it what you will, an impasse perhaps, but to my mind there appears to be a connection between the head lice delays and the AH product delays. I am only guessing at what appears, on the face of it, to be coincidental, but I am not buying into coincidental. The routine delays are a trend, clearly a trend is not a coincidence. Given that Eden has already revealed that there is increased interest in Sustain (other than from Sipcam), it's not out of the realms of possibility that Bayer would like far more than the AH products. So, it's also not out of the realms of possibility that the launch of the AH products are forming part of the negotiations. If Sustaine can also be a delivery platform on seeds (obviously it can do a lot more, but I think it could be applicable to seeds), then that aspect alone would be of great interest to Bayer - 3rd May 2019 Biological seed treatments have become an increasing important aspect of sustainable agriculture.In partnership with global leaders in biological solutions like Novozymes, Bayer SeedGrowth is at the forefront of biologicals development, expected to be one of the fastest growing seed treatment sectors in the near future. Full story - hTTp://news.agropages.com/News/NewsDetail---30331.htm 19th January 2019 Read how Martin Gruss, former Global Head Bayer SeedGrowth, will now hand over the business to his successor Boualem Saidi – and why the ambition of Bayer is clearly to strengthen its leading role in seed-applied technologies. Excerpt - Furthermore, we’d like to strengthen existing partnerships and build new ones, and accelerate alliances and co-operations. We’ll be present at leading industry events such as the ISF World Seed Congress and the European Seed Association (ESA) Annual Meeting, where we will exchange knowledge and establish dialogue with all key players along the value chain. Full interview - hTTps://www.seedgrowth.bayer.com/cases/the_new_setup_for_growth?id=%7B110AA661-CC0C-4A46-A117-CB9B9508ED2B%7D As the validation of Sustaine gathers momentum, the existing and new interest will have to break cover.......in one form or another!
wan
07/5/2019
10:08
There goes another one..news EU ban on chlorothalonil endorsed by member states hTTp://news.agropages.com/News/NewsDetail---29963.htm ……………………………… (Surprising to Reeves the Baker Pasty Lovers) The Conservation of Native Honey Bees Is Crucial hTTps://www.cell.com/trends/ecology-evolution/fulltext/S0169-5347(19)30117-X
supersonico
07/5/2019
09:27
Wan, Sorry to be thick: Bayer 'playing hard ball' in what sense? You're suggesting these are deliberate delays, used as bargaining chips. To what end?
brucie5
07/5/2019
09:27
Wan, Sorry to be thick: Bayer 'playing hard ball' in what sense? You're suggesting these are deliberate delays, used as bargaining chips. To what end?
brucie5
07/5/2019
08:28
Brucie...I continue to not hold my breath with regard to Bayer! Strictly in my opinion only, if we do not get further evidence/announcement in the interim, the impending launch of head lice product in September might be instructive! Clearly the CEO did not sign the original deal with Bayer, but he is stuck with it and Bayer has exclusivity......however, in terms of the animal health products, Eden's next-generation encapsulation technology might enable Eden to move on with another partner/distributor, or maybe it could get Bayer moving forward 'proper' on the animal health products.....or even agreeing to a much wider deal! As it stands though, my preference is with those partners that have 'effectively' demonstrated that they have got on with the job, Sipcam and Eastman. Sustaine is almost certainly of interest beyond Sipcam and Eastman (Eden has said as much) and validation of Sustaine is gaining momentum (and escape velocity from Bayer?). So, if Bayer are playing hard ball (which is my 'guess'), then they might have a harder fight on their hands than they envisaged/bargained for!
wan
06/5/2019
18:29
Good points, chrischas. My assumption is that well established partners on the ground are doing the door to door. Hence Mevalone sales this far, and Cedroz early doors emergency clearance in Italy.
brucie5
Chat Pages: Latest  280  279  278  277  276  275  274  273  272  271  270  269  Older
Your Recent History
LSE
EDEN
Eden Resea..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191020 03:06:10